Unlocking the Potential of CPN2 as a Drug Target and Biomarker

Target Name: CPN2

NCBI ID: G1370

CPN2

Unlocking the Potential of CPN2 as a Drug Target and Biomarker

Carboxypeptidase N (CPN) is a serine protein that plays a crucial role in various physiological processes in the body. CPN is responsible for breaking down peptides, which are short chains of amino acids that are derived from larger proteins. There are several subunits of CPN, and each subunit has distinct functions in different cellular processes. In this article, we will focus on the CPN2 subunit, which has great potential as a drug target and biomarker.

CNP2 Subunit: Structure and Function

The CPN2 subunit is a 14kDa protein that contains 254 amino acids. It is characterized by a single transmembrane domain and a highly conserved catalytic core. The CPN2 subunit has a unique feature, which is the presence of a N-terminal alkaline amino acid, which is unusual for a protein that is involved in peptide degradation.

The CPN2 subunit functions as a enzyme that catalyzes the hydrolysis of carboxy-peptides. This reaction involves the transfer of a proton from the substrate to the water, resulting in the formation of a new amino acid chain. The CPN2 subunit is specific for its target peptides, which are derived from the N-terminus of the cytoskeleton protein, calbindin.

CPN2 Interacts with Other Proteins

The CPN2 subunit interacts with several other proteins, including the calbindin protein itself. These interactions play a crucial role in the regulation of the activity of CPN2. The CPN2 subunit interacts with the N-terminus of calbindin, which is important for the stability and activity of the protein.

CPN2 as a Drug Target

The CPN2 subunit has been identified as a potential drug target due to its unique structure and function. The N-terminus of CPN2 is known to be involved in several signaling pathways, including the TGF-β pathway and the Wnt pathway. These signaling pathways are involved in various cellular processes, including cell growth, differentiation, and inflammation. Therefore, targeting the CPN2 N-terminus has the potential to modulate a wide range of cellular processes.

One approach to targeting CPN2 is to use small molecules that can modulate the activity of the subunit. For example, several small molecules have been shown to interact with the CPN2 N-terminus and to affect its activity. These small molecules include inhibitors of the protein tyrosine phosphatase (PTP), which is a enzyme that regulates the signaling pathways associated with the CPN2 N-terminus.

CPN2 as a Biomarker

The CPN2 subunit can also be used as a biomarker for various diseases, including cancer. The CPN2 subunit is overexpressed in many types of cancer, which suggests that it may be a useful target for cancer therapies. For example, several studies have shown that inhibitors of the CPN2 subunit have the potential to inhibit the growth and metastasis of various types of cancer, including breast, ovarian, and colorectal cancers.

Conclusion

In conclusion, the CPN2 subunit has great potential as a drug target and biomarker. Its unique structure and function make it an attractive target for small molecules that can modulate its activity. Further research is needed to fully understand the role of the CPN2 subunit in cellular processes and to develop effective therapies that target it.

Protein Name: Carboxypeptidase N Subunit 2

Functions: The 83 kDa subunit binds and stabilizes the catalytic subunit at 37 degrees Celsius and keeps it in circulation. Under some circumstances it may be an allosteric modifier of the catalytic subunit

The "CPN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CPN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets